BIIB:NASDAQ
Biogen Inc
248,35 US$
arrow_upward
+1,81%(+4,42) 1D
248,35 US$
0,00% (0,00)
bedtimeAfter hours
Closed: 6 ნოე, 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB...
Open
241,28 US$
High
250,03 US$
Low
240,00 US$
Mkt. cap
36,71 მლრდ.
Avg. vol.
1,31 მლნ.
Volume
1,00 მლნ.
P/E ratio
106,31
52-wk high
258,78 US$
52-wk low
151,83 US$
EPS
2,34 US$
Beta
0,10
Shares outstanding
147,82 მლნ.
No. of employees
8 ათ.
Open
241,28 US$
High
250,03 US$
Low
240,00 US$
Mkt. cap
36,71 მლრდ.
Avg. vol.
1,31 მლნ.
Volume
1,00 მლნ.
P/E ratio
106,31
52-wk high
258,78 US$
52-wk low
151,83 US$
EPS
2,34 US$
Beta
0,10
Shares outstanding
147,82 მლნ.
No. of employees
8 ათ.
News stories
From web sources and news partners
News Corp
·
1 დღის წინ
Biogen Inc. stock underperforms Thursday when compared to competitors
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOქრის ვიბახერ
Employees7,5 ათ.
Founded1978
Headquartersკემბრიჯი, მასაჩუსეტსი, ამერიკის შეერთებული შტატები
SectorHealth Care
Industry-
Websitebiogen.com